TPD52 and neoplasm: Our study found that the expression of TPD52 was upregulated in the advanced-stage tumor group (1.62 ± 0.4) and in the distant metastatic group of patients (5.25 ± 0.42) relative to lower stage tumor and non-metastatic groups, where its expression levels were increased 27.0 ± 1.68- and 14.2 ± 1.68-fold, respectively.